Orient: The 2026 ASCO Assembly is approaching, Chinese innovative drugs are making a strong breakthrough.

Orient released a research report stating that recently, the 2026 ASCO conference titles were officially announced, with 12 Chinese studies selected for LBA, demonstrating that the quality of Chinese research has been fully recognized internationally; the dual immune checkpoint inhibitors and antibody-drug conjugates are leading the race, establishing China's global leading position in the era of IO 2.0 and ADC 2.0, especially with Kangfang AK112 reaching Plenary Session, symbolizing the highest academic recognition of the clinical value of domestic innovative drugs. Subsequently, with the official release of regular abstracts on May 21 and the conference being officially held from May 29 to June 2, it is expected to accelerate the clinical advancement and authorization for a group of major domestic new drugs. The main points of view of Orient are as follows: Event Recently, the titles of the 2026 ASCO conference were officially announced, and the academic value, clinical value, and global competitiveness of domestic innovative drugs are expected to increase significantly. The ASCO (American Society of Clinical Oncology) Annual Meeting is the most authoritative and influential academic event in the global oncology field, known as the compass for global cancer treatment, will be held from May 29 to June 2. The number of Chinese studies selected for oral presentations and LBAs has reached a new high, moving from "breaking through in quantity" to "leading in quality." This ASCO includes a total of 63 studies selected for LBAs (latest breakthrough summaries), with 12 coming from China, a historical record high; at the same time, 94 Chinese studies were selected for oral presentations, showing a rapid growth in quantity over the past three years, with research covering multiple types of cancers, targets, and drugs, fully demonstrating the breadth and depth of China's innovative drug pipeline. The report believes that Chinese innovative drugs have evolved from "me-too/me-better" follow-up research to "FIC/BIC" original innovation, and this ASCO title announcement indicates a significant increase in the international influence and academic status of Chinese oncology research. Plenary Session achieves a historic breakthrough, with domestic dual immune checkpoint inhibitors defining the IO 2.0 era The Plenary Session is the most prestigious and high-quality section of ASCO, selecting only 4-5 breakthrough studies that have the potential to change clinical practice every year. This year, AKESO's Ivalsizumab's Harmoni-6 Phase III study was successfully selected. This not only represents the highest level of international recognition of the clinical value of Ivalsizumab but also signifies that domestic PD1/VEGF dual immune checkpoint inhibitors are leading the global oncology immune 2.0 era, with the potential to reshape the treatment standard for first-line lung cancer and become a new therapy that can change global clinical practice. Chinese pharmaceutical companies leading the dual immune checkpoint inhibitors and antibody-drug conjugates two major golden tracks This year's ASCO titles clearly indicate that dual immune checkpoint inhibitors and ADCs are the two core tracks in which Chinese innovative drugs have a global advantage: 1) IO 2.0: Domestic drugs are leading the way. In addition to Ivalsizumab, products from Kangfang such as Kandeni single antibodies, 3SBIOSSGJ-707, INNOVENT BIOIBI363, and Keystone Pharma CS2009 also made a prominent appearance, showing breakthrough efficacy in immunotherapy resistance, cold tumor treatment, and consolidating China's global leadership in the IO 2.0 field; 2) ADC 2.0: Companies such as Sichuan Biokin Pharmaceutical, Kolonbo, CSPC PHARMA, and HENLIUS concentrated on revealing the latest data in the oral presentation section, pushing ADCs from the back line to the front line and from single drug to combination treatment paradigm. Overall, dual immune checkpoint inhibitors and ADCs have become the core assets for Chinese innovative drugs to go global and compete on equal footing with international giants. Risk factors Risks of failed research and development of innovative drugs; Risks of intensified market competition; Risks of commercialization of innovative drugs, etc.